Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New York, New York 10021


Purpose:

To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152) and to establish the MTD at each of the different dosing schedules.


Study summary:

Patients receive intravenous DS-4152 by infusion twice weekly for 21 days, followed by 2 weeks of rest; courses may repeat. Patients undergo weekly follow-up. A punch biopsy will be obtained from patients with Kaposi's sarcoma.


Criteria:

Inclusion Criteria Patients must have: - Kaposi's sarcoma plus HIV infection OR metastatic solid tumor. - Life expectancy of at least 12 weeks. - NO symptomatic AIDS-defining opportunistic infection within the past 4 weeks. - Recovered from toxicity of any prior anticancer therapy. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Leukemia or lymphoma. - Current gastrointestinal bleeding by stool guaiac. - Extensive bone metastases or significant radiographic osteoporosis in patients with solid tumors. - Active heart disease such as uncontrolled angina, uncompensated congestive heart failure, or dysrhythmias requiring antiarrhythmics. - Acute intercurrent infection other than genital herpes. - Symptomatic or known central nervous system involvement (including brain metastases) unless stable and off therapy. Concurrent Medication: Excluded: - Other anticancer therapy. - Other investigational agents. Patients with the following prior conditions are excluded: - History of acute or chronic gastrointestinal bleeding or inflammatory bowel disease. - History of myocardial infarction within past 6 months. Prior Medication: Excluded: - Anticancer therapy within the past 3 weeks (6 weeks for nitrosourea or mitomycin C). - Investigational agents within the past 4 weeks.


NCT ID:

NCT00002342


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

New York, New York 10021
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: September 19, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.